New Developments in Incretins and SGLT Inhibitors

The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastric emptying and appetite suppression. Join host Dr. Steven Edelman and his guest Dr. Robert Henry, professor of medicine at the University of California, San Diego, and chief of both the section of endocrinology, metabolism and diabetes and the Center for Metabolic Research at the VA Medical Center in San Diego.